"FDA approves first treatment for certain patients with Erdheim-Chester disease, a rare blood cancer". U.S. Food and Drug ... Vemurafenib (INN), sold under the brand name Zelboraf, is a medication used for the treatment of late-stage melanoma. It is an ... approved vemurafenib for the treatment of people with Erdheim-Chester disease (ECD), a rare type of histiocytic neoplasm. A ... "Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology ...

... tumors including glioblastoma and pleomorphic xanthoastrocytoma as well as inflammatory diseases like Erdheim-Chester disease. ... "FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of ... Mutations in the BRAF gene can cause disease in two ways. First, mutations can be inherited and cause birth defects. Second, ... Vemurafenib (RG7204 or PLX4032) was licensed by the US Food and Drug Administration as Zelboraf for the treatment of metastatic ...